Home LiteratureArticle Details
PMID: 11160726 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Journal of virology ·Vol. 75 ·No. 5 ·2001-03-00 ·Pages 2224-34

Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA

Abstract

The great difficulty in eliciting broadly cross-reactive neutralizing antibodies (NAbs) against human immunodeficiency virus type 1 (HIV-1) isolates has been attributed to several intrinsic properties of their viral envelope glycoprotein, including its complex quaternary structure, extensive glycosylation, and marked genetic variability. Most previously evaluated vaccine candidates have utilized envelope glycoprotein from a single virus isolate. Here we compare the breadth of NAb and protective immune response following vaccination of pigtailed macaques with envelope protein(s) derived from either single or multiple viral isolates. Animals were challenged with Simian/human immunodeficiency virus strain DH12 (SHIV(DH12)) following priming with recombinant vaccinia virus(es) expressing gp160(s) and boosting with gp120 protein(s) from (i) LAI, RF, 89.6, AD8, and Bal (Polyvalent); (ii) LAI, RF, 89.6, AD8, Bal, and DH12 (Polyvalent-DH12); (iii) 89.6 (Monovalent-89.6); and (iv) DH12 (Monovalent-DH12). Animals in the two polyvalent vaccine groups developed NAbs against more HIV-1 isolates than those in the two monovalent vaccine groups (P = 0.0054). However, the increased breadth of response was directed almost entirely against the vaccine strains. Resistance to SHIV(DH12) strongly correlated with the level of NAbs directed against the virus on the day of challenge (P = 0.0008). Accordingly, the animals in the Monovalent-DH12 and Polyvalent-DH12 vaccine groups were more resistant to the SHIV(DH12) challenge than the macaques immunized with preparations lacking a DH12 component (viz. Polyvalent and Monovalent-89.6) (P = 0.039). Despite the absence of any detectable NAb, animals in the Polyvalent vaccine group, but not those immunized with Monovalent-89.6, exhibited markedly lower levels of plasma virus than those in the control group, suggesting a superior cell-mediated immune response induced by the polyvalent vaccine.

MeSH Terms
AIDS Vaccines/immunology Animals HIV Antibodies/blood HIV Envelope Protein gp120/genetics,immunology HIV Envelope Protein gp160/genetics,immunology HIV Infections/prevention & control HIV-1/classification,genetics,immunology,metabolism Macaca nemestrina Neutralization Tests RNA, Viral/blood SAIDS Vaccines/immunology Simian Acquired Immunodeficiency Syndrome/prevention & control Simian Immunodeficiency Virus/pathogenicity Vaccination Vaccines, Synthetic/immunology Vaccinia virus/genetics,immunology
Chemicals
AIDS Vaccines HIV Antibodies HIV Envelope Protein gp120 HIV Envelope Protein gp160 RNA, Viral SAIDS Vaccines Vaccines, Synthetic
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Cho M W
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA. mcho@nih.gov
Kim Y B
Lee M K
Gupta K C
Ross W
Plishka R
Buckler-White A
Igarashi T
Theodore T
Byrum R
Kemp C
Montefiori D C
Martin M A
References (56)
56 references, click to expand
  1. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1882-6 PMID: 8446603
  2. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Nat Med. 1999 Feb;5(2):204-10 PMID: 9930869
  3. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  4. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
    Vaccine. 1993 Oct;11(13):1347-55 PMID: 7507625
  5. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    J Virol. 1994 Jul;68(7):4636-42 PMID: 7515975
  6. Membrane rearrangement and vesicle induction by recombinant poliovirus 2C and 2BC in human cells.
    Virology. 1994 Jul;202(1):129-45 PMID: 8009827
  7. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):5142-55 PMID: 8035514
  8. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  9. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  10. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  11. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
    AIDS. 1995 Jun;9(6):F1-6 PMID: 7662189
  12. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):9004-8 PMID: 7568061
  13. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  14. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    J Infect Dis. 1996 Jan;173(1):60-7 PMID: 8537683
  15. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  16. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge.
    AIDS. 1995 Dec;9(12):F13-8 PMID: 8605046
  17. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
    J Virol. 1996 Jul;70(7):4361-9 PMID: 8676459
  18. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
    Cell. 1996 Jun 28;85(7):1149-58 PMID: 8674120
  19. Infection of chimpanzee peripheral blood mononuclear cells by human immunodeficiency virus type 1 requires cooperative interaction between multiple variable regions of gp120.
    J Virol. 1996 Oct;70(10):7318-21 PMID: 8794390
  20. Phenotypic analysis of antigen-specific T lymphocytes.
    Science. 1996 Oct 4;274(5284):94-6 PMID: 8810254
  21. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):993-9 PMID: 8827215
  22. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
    AIDS Res Hum Retroviruses. 1997 Jul 20;13(11):913-22 PMID: 9223407
  23. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing.
    J Infect Dis. 1997 Aug;176(2):362-73 PMID: 9237701
  24. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
    J Virol. 1997 Nov;71(11):8141-8 PMID: 9343164
  25. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9475-81 PMID: 9371609
  26. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Nat Med. 1997 Dec;3(12):1389-93 PMID: 9396610
  27. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
    J Virol. 1998 Mar;72(3):2509-15 PMID: 9499115
  28. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  29. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    J Virol. 1999 Dec;73(12):10199-207 PMID: 10559336
  30. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus.
    Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14049-54 PMID: 10570196
  31. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  32. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
  33. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    J Virol. 2000 Mar;74(6):2960-5 PMID: 10684319
  34. Higher western blot immunoreactivity of glycoprotein 120 from R5 HIV type 1 isolates compared with X4 and X4R5 isolates.
    AIDS Res Hum Retroviruses. 2000 May 20;16(8):765-75 PMID: 10826483
  35. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.
    J Virol. 2000 Oct;74(20):9749-54 PMID: 11000249
  36. Assessment of HIV vaccine development: past, present, and future.
    Adv Pharmacol. 2000;49:263-314 PMID: 11013767
  37. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019-35 PMID: 11153085
  38. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
    Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 PMID: 3095828
  39. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
    J Virol. 1988 Jan;62(1):139-47 PMID: 3257102
  40. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.
    J Clin Microbiol. 1988 Feb;26(2):231-5 PMID: 3422647
  41. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  42. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  43. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  44. Product review. New mammalian expression vectors.
    Nature. 1990 Nov 1;348(6296):91-2 PMID: 2234068
  45. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.
    Nature. 1991 Aug 1;352(6334):436-8 PMID: 1677743
  46. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  47. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    AIDS Res Hum Retroviruses. 1991 Jul;7(7):615-20 PMID: 1768463
  48. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Nature. 1992 Feb 20;355(6362):728-30 PMID: 1741059
  49. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.
    J Virol. 1993 Jan;67(1):577-83 PMID: 8416384
  50. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    J Infect Dis. 1993 Mar;167(3):533-7 PMID: 8095059
  51. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.
    AIDS. 1993 Jan;7(1):15-21 PMID: 7680205
  52. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    J Infect Dis. 1998 May;177(5):1230-46 PMID: 9593008
  53. Antigen presentation and related immunological aspects of HIV-1 vaccines.
    AIDS. 1998;12 Suppl A:S97-112 PMID: 9632991
  54. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  55. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
    Vaccine. 1998 Nov;16(19):1803-11 PMID: 9795384
  56. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.75.5.2224-2234.2001
Email
mcho@nih.gov
Published
2001-03-00
Pages
2224-34
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114806
Subset
IM
Grants
NIAID NIH HHS · AI-85343 · United States
External Links
PubMed source DOI: 10.1128/JVI.75.5.2224-2234.2001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2